Topic · Product

Zepbound

10 articles

Latest Zepbound articles

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.

Zepboundneutral

Eli Lilly Zepbound

Sep 30, 2026 · byMarketWatch

STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.

Zepboundcritical

Eli Lilly Zepbound

Sep 30, 2026 · bySTAT

‘Astonishing’ weight loss when GLP-1 drug used with second medication

Tirzepatide, sold as Mounjaro and Zepbound, is our most potent weight-loss drug, but it can be made even more effective when combined with a complementary medicine

Zepbound

Sep 30, 2026 · byNew Scientist

Novo Nordisk’s next-gen weight loss drug outperforms Zepbound in new trial

Novo Nordisk says its potential Wegovy successor helped patients lose more weight than Zepbound in a major clinical trial.

Novo Nordisk Wegovy Zepbound

Sep 28, 2026 · byThe Hill

Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat

Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond appetite suppression. If confirmed in humans, the finding could help explain the drug’s powerful benefits and inspire more comprehensive treatments for obesity and diabetes.

Zepbound

Sep 26, 2026 · byScienceDaily

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

Zepbound

Sep 22, 2026 · byMarketWatch

Stopping Ozempic may raise heart attack and stroke risk

A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.

Zepbound

Sep 21, 2026 · byScienceDaily

AI uncovers hidden Ozempic side effects across 400,000 Reddit posts

AI analysis of 400,000 Reddit posts found that users of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reported unexpected symptoms including menstrual changes, chills, hot flashes, and fatigue. Researchers cannot say the medications caused these problems, but the patterns may reveal overlooked signals worth studying.

Reddit Zepbound

Sep 13, 2026 · byScienceDaily

Ozempic and Wegovy may raise hair loss risk in some men

GLP-1 drugs such as Ozempic, Wegovy, and Zepbound may increase hair-loss risk by 7% in men who are already genetically susceptible to male-pattern baldness. The findings suggest thinning hair may not be caused only by rapid weight loss and could also reflect a biological link between GLP-1 activity and hair follicles.

Zepbound

Sep 13, 2026 · byScienceDaily

Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over dieting.

Wegovy Zepbound

Oct 10, 2024 · byFortune